teplizumab sold brand name tzield humanized monoclonal antibody first approved treatment indicated delay onset stage type diabetes people stage fc region antibody engineered fc receptor nonbinding fnb mechanisms action teplizumab appear involve weak agonistic activity signaling via cell complex associated development anergy unresponsiveness andor apoptosis particularly unwanted activated teff cells addition regulatory cytokines released regulatory cells expanded may lead reestablishment immune tolerance teplizumab approved medical use united states november us food drug administration fda considers firstinclass teplizumab indicated delay onset stage type diabetes people aged eight years age older stage teplizumab developed university chicago partnership ortho pharmaceuticals developed macrogenics including collaboration eli lilly conduct first phase clinical trial earlyonset type initial phase trial conducted macrogenics failed meet primary drug acquired provention bio restarted development based subset analysis original teplizumab used clinical trials aim protecting remaining Î²cells newly diagnosed type diabetes immunomodulatory agents may restore normal glucose control provided early stages disease stage still enough beta cells maintain teplizumab evaluated treatment renal allograft rejection induction therapy islet transplant recipients psoriatic phase ii study showed teplizumab could delay development diabetes family members type diabetics showing signs progression towards diabetes two years single treatment renewing interest use preventive rather therapeutic treatment highrisk immune activation dostarlimab ibalizumab httpsenwikipediaorgwikiteplizumab